GlassScriptPhysician profile
John J Richards
NPI 1215193651
$4,595.89
in general payments reported to CMS, 2019-2025
25 companies · $558 in 2025
The $558 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $128 · 2021: $936 · 2022: $901 · 2023: $882 · 2024: $750 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $838.79 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $765.96 | 2019-2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $482.65 | 2021-2025 | Trelegy Ellipta |
| Lilly USA, LLC | $427.03 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $357.64 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $248.42 | 2022-2025 | Freestyle Libre, Freestyle Libre 3, Freestyle Libre 2 |
| Abbvie INC. | $241.64 | 2021-2023 | |
| Amgen INC. | $232.74 | 2019-2024 | Evenity, Prolia, Repatha |
| Janssen Pharmaceuticals, INC | $195.70 | 2020-2021 | |
| Preventric Diagnostics, INC. | $169.88 | 2021 | |
| Novartis Pharmaceuticals Corporation | $114.51 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $83.32 | 2019-2022 | |
| Exact Sciences Corporation | $68.91 | 2024-2025 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $68.08 | 2021 | |
| Ironshore Pharmaceuticals INC. | $58.49 | 2019-2023 | Jornay Pm |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $49.07 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $47.61 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.53 | 2023 | Xifaxan |
| Dexcom, INC. | $23.44 | 2024 | Dexcom G6 Transmitter |
| Allergan, INC. | $22.62 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $18.92 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.06 | 2023 | |
| Daiichi Sankyo INC. | $12.49 | 2021 | |
| Sanofi Pasteur INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Richards listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.